Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial

BACKGROUND: In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be intensified by addition of cetuximab, a monoclonal antibody that blocks the ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Habl, G, Potthoff, K, Haefner, MF, Abdollahi, A, Hassel, JC, Boller, E, Indorf, M, Debus, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751099/
https://www.ncbi.nlm.nih.gov/pubmed/23855804
http://dx.doi.org/10.1186/1471-2407-13-345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751099/
https://www.ncbi.nlm.nih.gov/pubmed/23855804
http://dx.doi.org/10.1186/1471-2407-13-345

Ejemplares similares